|
N. of RCT (%)
|
51 (91.1)
|
5 (8.9)
|
56 (100.0)
|
|
N. of participants (%) (males/females)
|
6,499 (93.4) (1611/4888)
|
457 (6.6) (102/355)
|
6956 (100.0) (1713/5243)
|
|
Mean N. of participants
|
127.4 ± 113.3
|
91.4 ± 33.5
|
124.2 ± 109.0
|
|
Mean age (year)a
|
40.2 ± 4.0
|
15.5 ± 0.3
|
38.7 ± 8.1
|
|
N. of case definitions for inclusion criteria (%)b,c
|
|
CDC 1994 (Fukuda)
|
37 (72.5)
|
5 (100.0)
|
42 (75.0)
|
|
Schluederberg 1992
|
2 (3.9)
|
–
|
2 (3.6)
|
|
Oxford 1991 (Sharpe)
|
12 (23.5)
|
1 (20.0)
|
13 (23.2)
|
|
CDC 1988 (Holmes)
|
3 (5.9)
|
–
|
3 (5.4)
|
|
Lloyd 1988
|
2 (3.9)
|
–
|
2 (3.6)
|
|
Others
|
5 (9.8)
|
1 (20.0)
|
6 (10.7)
|
|
RCTs with pharmacological intervention (N, %)
|
23 (92.0)
|
2 (8.0)
|
25 (100.0)
|
|
Kinds of interventions (%)
|
20 (90.9)
|
2 (9.1)
|
22 (100.0)
|
|
Mean treatment period (weeks)
|
11.0 ± 7.0
|
8.5 ± 0.7
|
10.8 ± 6.8
|
|
RCTs with non-pharmacological intervention (N, %)
|
26 (89.7)
|
3 (10.3)
|
29 (100.0)
|
|
Kinds of interventionsd
|
18 (94.7)
|
2 (10.5)
|
19 (100.0)
|
|
Mean treatment period (weeks)
|
17.1 ± 7.1
|
30.7 ± 15.1
|
18.5 ± 8.9
|
|
RCTs with combined interventions (N, %)
|
2 (100.0)
|
–
|
2 (100.0)
|
|
Kinds of interventions (%)
|
4 (100.0)
|
–
|
4 (100.0)
|
|
Mean treatment period (weeks)
|
26 ± 2.8
|
–
|
26 ± 2.8
|
|
Primary measurements in 55 RCTs (n, %)c,e
|
|
Checklist Individual Strength (CIS)
|
20 (35.7)
|
|
36-item Short Form health survey (SF-36)
|
18 (32.1)
|
|
Sickness Impact Profile (SIP)
|
8 (14.3)
|
|
Chalder Fatigue Scale
|
8 (14.3)
|
|
Visual Analogue Scale (VAS)
|
6 (10.7)
|
|
Clinical Global Impression (CGI)
|
5 (8.9)
|
|
Karnofsky Performance Scale (KPS)
|
3 (5.4)
|
|
School attendance rate (SAR)
|
3 (5.4)
|
|
Multidimensional Fatigue Inventory (MFI)
|
2 (3.6)
|
|
Fatigue Severity Scale (FSS)
|
2 (3.6)
|
|
Others
|
21 (37.5)
|
